DB:NZW2

Stock Analysis Report

Executive Summary

Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Molecular Templates's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NZW2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.5%

NZW2

8.1%

DE Biotechs

7.2%

DE Market


1 Year Return

143.8%

NZW2

-5.4%

DE Biotechs

-17.5%

DE Market

Return vs Industry: NZW2 exceeded the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: NZW2 exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

NZW2IndustryMarket
7 Day9.5%8.1%7.2%
30 Day-14.8%-11.8%-22.3%
90 Day2.4%-22.7%-26.1%
1 Year143.8%143.8%-5.2%-5.4%-14.9%-17.5%
3 Yearn/a17.6%16.3%-18.7%-25.7%
5 Yearn/a-5.1%-7.5%-17.8%-29.1%

Price Volatility Vs. Market

How volatile is Molecular Templates's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Molecular Templates undervalued compared to its fair value and its price relative to the market?

6.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NZW2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NZW2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NZW2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NZW2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NZW2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NZW2 is overvalued based on its PB Ratio (6.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Molecular Templates forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

13.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NZW2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NZW2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NZW2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NZW2's revenue (25% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: NZW2's revenue (25% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NZW2's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Molecular Templates performed over the past 5 years?

-45.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NZW2 is currently unprofitable.

Growing Profit Margin: NZW2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NZW2 is unprofitable, and losses have increased over the past 5 years at a rate of -45.5% per year.

Accelerating Growth: Unable to compare NZW2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NZW2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: NZW2 has a negative Return on Equity (-67.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Molecular Templates's financial position?


Financial Position Analysis

Short Term Liabilities: NZW2's short term assets ($139.9M) exceed its short term liabilities ($35.8M).

Long Term Liabilities: NZW2's short term assets ($139.9M) exceed its long term liabilities ($35.4M).


Debt to Equity History and Analysis

Debt Level: NZW2's debt to equity ratio (2.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if NZW2's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: NZW2 has a low level of unsold assets or inventory.

Debt Coverage by Assets: NZW2's debt is covered by short term assets (assets are 47.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NZW2 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NZW2 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of -34.1% each year.


Next Steps

Dividend

What is Molecular Templates's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NZW2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NZW2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NZW2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NZW2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NZW2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Eric Poma (47yo)

11.17s

Tenure

US$3,767,677

Compensation

Dr. Eric E. Poma, Ph.D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as it's President. Dr. Poma served as Vice President of Business Deve ...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD3.77M) is above average for companies of similar size in the German market ($USD1.36M).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Eric Poma
CEO, Chief Scientific Officer & Director11.17yrsUS$3.77m0.53% $3.1m
Jason Kim
President & COO10.17yrsUS$1.55m0.12% $689.4k
Adam Cutler
Chief Financial Officer2.33yrsUS$1.07mno data
Kurt Elster
Executive Vice President of Corporate Developmentno datano datano data
Jack Higgins
Executive VP of Operations & Head of Manufacturingno datano datano data
Erin Willert
Executive Vice President of R&Dno datano datano data
Jen-Sing Liu
Executive Vice President of Manufacturingno datano datano data
Nenad Sarapa
Senior Vice President of Clinical Development2.33yrsno datano data
Conrad Jordaan
Senior Vice President of Finance & Corporate Controller2.33yrsno datano data
Roger Waltzman
Chief Medical Officer1.08yrsno datano data

2.3yrs

Average Tenure

45yo

Average Age

Experienced Management: NZW2's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Poma
CEO, Chief Scientific Officer & Director11.17yrsUS$3.77m0.53% $3.1m
Michel Klein
Member of Scientific Advisory Boardno datano datano data
David Hoffmann
Director2.58yrsUS$131.29kno data
Harold Selick
Chairmanno dataUS$146.29k0.089% $519.6k
Kevin Lalande
Directorno dataUS$134.29kno data
David Hirsch
Director2.58yrsUS$132.79kno data
Burkhard Jansen
Member of Scientific Advisory Boardno datano datano data
Neil Berinstein
Member of Scientific Advisory Boardno datano datano data
Jonathan Lanfear
Director1.83yrsno datano data
Scott Morenstein
Director2.58yrsUS$123.79kno data

2.6yrs

Average Tenure

51.5yo

Average Age

Experienced Board: NZW2's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.6%.


Top Shareholders

Company Information

Molecular Templates, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Molecular Templates, Inc.
  • Ticker: NZW2
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$644.548m
  • Listing Market Cap: US$581.318m
  • Shares outstanding: 45.65m
  • Website: https://www.mtem.com

Number of Employees


Location

  • Molecular Templates, Inc.
  • 9301 Amberglen Boulevard
  • Suite 100
  • Austin
  • Texas
  • 78729
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTEMNasdaqCM (Nasdaq Capital Market)YesNew Common SharesUSUSDAug 2017
NZW2DB (Deutsche Boerse AG)YesNew Common SharesDEEURAug 2017

Biography

Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 00:42
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.